Royalty Pharma

$39.78 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Royalty Pharma

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Stock Analysis

last close $40.51
1-mo return -8.1%
3-mo return 2.8%
avg daily vol. 2.36M
52-week high 47.1
52-week low 34.86
market cap. $17.4B
forward pe 13.5
annual div. 0.76
roe 11.3%
ltg forecast 11.2%
dividend yield 1.88%
annual rev. $2.3B
inst own. 64.3%
baraka

Subscribe now for daily local and international financial news

Subscribe